Otilimab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | GMCSF |
Clinical data | |
Synonyms | GSK3196165, MOR103 |
ATC code |
|
Identifiers | |
CAS Number | |
UNII | |
Chemical and physical data | |
Formula | C6322H9768N1684O1966S44 |
Molar mass | 142.23 g/mol |
Otilimab (GSK3196165, MOR103) (INN) is a monoclonal antibody designed for the treatment of osteoarthritis and rheumatoid arthritis.[1][2]
This drug is being developed by GlaxoSmithKline.
References
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.